← Eichor
Condition: High Grade B Cell Lymphoma Hgbcl Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: High Grade B Cell Lymphoma Hgbcl

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Phase 2 · 77 location(s) · Allogene Therapeutics · NCT06500273DALY II USA/ MB-CART2019.1 for DLBCL
Phase 2 · 32 location(s) · Miltenyi Biomedicine GmbH · NCT04792489Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade
Phase 2 · 7 location(s) · Istituto Clinico Humanitas · NCT06918912A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Ref
Phase 1 · 1 location(s) · GenomeFrontier Therapeutics TW Co., Ltd. · NCT06703892A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Phase 1 · 22 location(s) · Incyte Corporation · NCT07195916Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggress
Phase 2 · 86 location(s) · National Cancer Institute (NCI) · NCT06649812NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)
Phase 2/Phase 3 · 4 location(s) · Health Institutes of Turkey · NCT07502118
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.